3. IPPOSI? Who?IPPOSI
Mission
We expedite development of and
patient access to innovative therapies
Unique partnership of Patient Groups,
Industry and Science
Priorities
• Bring a patient perspective to clinical research, connected health, health economics
• Actively influence policy that impacts on research + access to innovative therapies
“Putting patients in policy and medicines development”
5. IPPOSI Funding
• Grant from Department of Health
(via Health Research Board)
• Industry membership fee
6. Goals for patient involvement in HTA?
• Democratic
• Scientific
• Instrumental
• Developmental
7. IPPOSI Partnership with HIQA + NCPE
• HIQA have patient involvement on the advisory
board of individual HTAs
• Annual HTA Training for patients through IPPOSI
• List of products under NCPE rapid review available on
IPPOSI website
• Irish patient groups exploring measuring patient
outcomes with the NCPE
8. Annual HTA & Decision Training
2016:
“incorporating the patient
perspective”
10. Other jurisdictions?
• European Patients Forum Survey
• SMC
• Patient Group Partners
• Submission Form
• Patient Org. Registration Form
• Guidance (Good Example)
• Public Involvement Network Advisory Group
11. Values and Quality Standards for PPI
• HIQA
• Guidelines for Stakeholder
Engagement in HTA
• EUnetHTA
• Stakeholder Forum
• HTAi
• Vision: that patient and
citizen perspectives improve
HTA
http://www.htai.org/interest-groups/patient-and-citizen-
involvement/pcig-resources/hta-resources.html
12. Irish Educational Platform
• John Dowling, Men Against Cancer
• Caitriona Dunne, Fighting Blindness
• Joan Jordan, MS Ireland
• Katie Murphy, CF Ireland
• Rachel Lynch, FibroIreland
• Damien Peelo, COPD Support Ireland
• Julie Power, Vasculitis Ireland Awareness
• Sharon Thompson, Rare Dis. + Palliative care
8 Irish Trainees
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial
contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
13. Why?, Who?, When?, How?
EXAMPLES:
• In clinical trial methodology / outcomes
• Incorporate patient preferences in QALY
• Adjusting clinical / review criteria
• In between NCPE recommendation + HSE decision
14. Take Home Messages
• Develop clear policies for PPI
• Early & Ongoing Involvement
• Need Education/Training for all
@IPPOSI
www.ipposi.ie
Editor's Notes
There is little resistance to the fact that patients should be involved, but how, at what stage, and why?
Foster the early engagement of patient organisations in clinical trials to integrate quality of life, social and ethical information into the evidence-collection for HTA agencies.
Involve patient organisations in gathering data post-marketing authorisation to inform long-term relative effectiveness assessments.